ABX · Abacus Global Management, Inc.

Current Thesis

Abacus Global Management's fee-management pivot remains the business story, but the September 18, 2026 close of $8.77 has invalidated the published recovery thesis by breaking its $9.00 weekly-close condition. That is the material change since the September 6 note; the threshold cannot be lowered retrospectively to preserve the case. The market observation establishes a price-structure failure, not the failure of the underlying business.

For the shelf-supported recovery case, the narrative is dead — the September 18 week ended below the published boundary despite the repurchase program announced August 13. This classification is an inference from the breached condition. The broader conversion of life-settlement income into recurring management fees still requires operating evidence.

The company did publish new material after the previous review: its September 9 announcement concerned participation in the September 14–16 Barclays financial-services conference. That attention event has elapsed; the release index reviewed September 20 contains no subsequent earnings or guidance announcement. Company releases

Bullish and bearish views on Abacus Global Management, Inc.

The model's bull view on Abacus Global Management, Inc. (ABX), in brief: Capital formation supports the pivot. The August 6, 2026 results reported $544.2 million raised into longevity funds during the first half. This is measured fundraising evidence; it does not establish the subsequent recurring-fee contribution. Second-quarter results Adjusted… The bear view: The published boundary has failed. The September 18, 2026 adjusted close of $8.77 is below the $9.00 weekly threshold specified in the September 6 public note. Preserving that threshold records the failure rather than substituting a new thesis retrospectively. Reported earnings… Both cases follow in full.

Bull Case

• Capital formation supports the pivot. The August 6, 2026 results reported $544.2 million raised into longevity funds during the first half. This is measured fundraising evidence; it does not establish the subsequent recurring-fee contribution. Second-quarter results
• Adjusted earnings met management's case. On August 6, 2026, Abacus reported second-quarter adjusted diluted earnings per share (EPS) of $0.28 and maintained full-year adjusted EPS guidance of $1.00–$1.05. Those disclosures support the operating argument without reversing the September price invalidation. Second-quarter results

Bear Case

• The published boundary has failed. The September 18, 2026 adjusted close of $8.77 is below the $9.00 weekly threshold specified in the September 6 public note. Preserving that threshold records the failure rather than substituting a new thesis retrospectively.
• Reported earnings remain materially different. Second-quarter 2026 diluted EPS under generally accepted accounting principles (GAAP) was $0.07, against adjusted EPS of $0.28, according to the August 6 disclosure. The adjusted measure alone does not describe reported profitability. Second-quarter results
• Proposed securities sales remain visible. The company's filing index lists Forms 144 dated September 18, 2026. These are notices of proposed sales; the index does not establish completed transactions or their effect on that day's price. Company filing index

Setup & Price Structure

The supplied split- and dividend-adjusted series records a September 18, 2026 close of $8.77, a three-month price change of −8.3%, and a 14-day relative strength index (RSI) of 28.8. The same snapshot places the shares 26.9% below the adjusted 52-week high of $12.00. These are measured observations; the low RSI alone supplies no evidence that a recovery has begun.

The August 13 repurchase authorization was $100 million, according to the company's announcement. Authorization does not establish execution, and the September 18 proposed-sale filings do not establish realized selling pressure. Together they identify potential opposing sources of demand and supply, without measuring their balance. Company releases Company filing index

No dated moving-average series, short-interest measure or retail-participation sample is available in the evidence reviewed September 20. A crowding conclusion is therefore unsupported.

Catalyst Calendar (next 30 days)

For September 20–October 20, 2026, no company-scheduled event is listed on the investor-relations calendar reviewed September 20. The September 14–16 Barclays conference appears among past events. The calendar supplies no confirmed next earnings date. Company calendar

The September 6 note's estimated September 30 court ruling lacks a confirmed court date in the available evidence and is not retained as a scheduled catalyst. The next quarterly results remain the operating checkpoint against management's August 6 third-quarter adjusted-EPS guidance of $0.26–$0.28; their publication date is unconfirmed. Second-quarter results

What Would Change Our Mind

The support failure has already settled the original price test: a weekly close below $9.00 invalidates the published recovery thesis, and September 18, 2026 ended at $8.77. A subsequent weekly close above $9.00 would reopen assessment of the structure but would not erase this recorded failure.

A separate operating reassessment would require the next results to meet the August 6 third-quarter adjusted-EPS range of $0.26–$0.28 and retain the full-year $1.00–$1.05 range. A reported result below that quarterly range or a reduction in the annual range would defeat that conditional operating case. Second-quarter results

Correlation Notes

This remains a single-company assessment: the September 18, 2026 price snapshot contains no peer-return series from which to establish correlation. The longevity-fund fundraising disclosed August 6 supplies a company-specific operating driver. The evidence does not establish that a financial-sector or cryptocurrency rally would repair the failed price structure.